HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm
  • CME

Watch this on-demand Webcast capturing expert presentations focused on the latest treatment strategies for patients with HER2+ breast cancer in the early and metastatic settings.
Neelima Denduluri, MD, FASCO
Lee Schwartzberg, MD, FACP
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: August 11, 2020 Expiration: August 10, 2021
Multimedia HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm
This program is divided into short segments that you can review from the Activity landing page.
Introduction to HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm (1 min)
View this brief introduction to the experts who will present clinical perspectives on leveraging HER2-targeted therapies for HER2-positive breast cancer.
Launch Introduction to HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm (1 min)
Expert Guidance on the Evolving Therapeutic Landscape for HER2-Positive Early-Stage Breast Cancer (42 mins)
Get up to date on the latest evidence informing optimal treatment of HER2-positive early breast cancer, including (neo)adjuvant strategies, risk-based treatment selection, and managing adverse events.
Launch Expert Guidance on the Evolving Therapeutic Landscape for HER2-Positive Early-Stage Breast Cancer (42 mins)
HER2-Positive Metastatic Breast Cancer: Current Status and Promising Agents on the Horizon (32 mins)
Learn how to leverage new and established HER2-targeted agents for HER2-positive metastatic breast cancer across multiple lines of therapy. Then, review expert answers to clinician questions on HER2-positive disease from a live CCO Webinar.
Launch HER2-Positive Metastatic Breast Cancer: Current Status and Promising Agents on the Horizon (32 mins)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan optimal adjuvant and/or extended adjuvant treatment strategies for patients with HER2-positive early-stage breast cancer
  • Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer
  • Apply the latest clinical evidence on HER2-targeted agents to treat patients with HER2 low–expressing tumors
  • Plan effective therapy for patients with HER2-positive metastatic breast cancer and CNS metastases
  • Evaluate emerging research, the mechanisms of action, and the role of novel HER2-targeted therapies in clinical investigation for patients with HER2-positive metastatic breast cancer

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Puma Biotechnology, Inc.
Seattle Genetics

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Neelima Denduluri, MD, FASCO

Clinical Assistant Professor
Georgetown University
Washington, DC
Medical Oncologist
Virginia Cancer Specialists
Co-Director, Virginia Cancer Specialists Research Program
Associate Chair, US Oncology Breast Cancer Research Committee
Arlington, Virginia

Neelima Denduluri, MD, FASCO, has disclosed that she has received funds for research support paid to her institution from Amgen, AstraZeneca, Daiichi, Genentech, and Novartis.
Lee Schwartzberg, MD, FACP

Medical Director
West Cancer Center and Research Institute
Professor of Medicine
University of Tennessee
Health Science Center
Memphis, Tennessee

Lee Schwartzberg, MD, FACP, has disclosed that he has received funds for research support from Amgen; consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Genomic Health, Helsinn, Myriad, Napo, Spectrum, and Pfizer; and other financial or material support from Bayer.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with breast cancer.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to integrate HER2-targeted agents into the treatment of patients with breast cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 11, 2020, through August 10, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

On-demand Webcast featuring expert discussion of new therapies for relapsed/refractory HER2-positive metastatic breast cancer, from a live CCO Webinar

Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD person default Cristina Saura, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: September 11, 2020 Expired: September 10, 2021

Expert commentary from Cristina Saura, MD, PhD, with answers to frequently asked questions on managing HER2-positive metastatic breast cancer from CCO

person default Cristina Saura, MD, PhD Released: September 11, 2020

Commentary from Adam Brufsky, MD, on managing interstitial lung disease during trastuzumab deruxtecan treatment for HER2-positive metastatic breast cancer

Adam M. Brufsky, MD, PhD Released: September 10, 2020

From Clinical Care Options (CCO), watch video of expert discussions of testing for and targeting of HER2, HER3, and TROP2 in metastatic breast cancer

Mark D. Pegram, MD Michael F. Press, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.25 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: September 10, 2020 Expired: September 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?